Page 9 - Lupin

Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high

In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma index

Here's a Bull Spread Strategy on Lupin by Nandish Shah of HDFC Securities

Primary trend of the stock is positive where stock price is trading above its 200-day SMA

Lupin gets USFDA nod to market drug for treating relapsing sclerosis

Lupin said it has received approval from the US health regulator to market generic Dimethyl Fumarate delayed-release capsules used for treatment of relapsing forms of multiple sclerosis in adults

As domestic sales decline, drug makers focus on exports to sustain growth

During April-July, drug makers exported products worth $ 7.4 billion, a growth of 9.5 per cent on year on year basis

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US

According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US

BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs

Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE

Charts show bulls are making a strong comeback: Nilesh Jain of Anand Rathi

The momentum indicators and oscillators on the weekly scale are very well on buy mode. The volatility index --India VIX -- has also started cooling down which is giving comforts to the bulls

Lupin launches generic rheumatoid arthritis drug 'Leflunomide' in US market

Drug maker Lupin on Wednesday said it has launched Leflunomide tablets, used to treat rheumatoid arthritis, in the US market. The company has launched the product in 10 mg and 20 mg strengths after receiving the approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement. The product would be manufactured at drug maker's Pithampur (Unit I) facility in Madhya Pradesh, it added. The Mumbai-based company's product is the generic equivalent of Sanofi-Aventis US LLC's Arava tablets and is indicated for the treatment of adults with active rheumatoid arthritis (RA). As per IQVIA MAT June data, Leflunomide tablets had an annual sales of around USD 42 million in the US.

Launch of inhalation product improves Lupin's revenue visibility

More US launches and uptick in the Indian market are key near-term triggers

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Lupin gets USFDA approval for asthmatic symptoms prevention drug

Drug major Lupin on Tuesday said it has received approval from the US health regulator for its Albuterol Sulfate Inhalation Aerosol, used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms. The approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin said it has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation. Vinita Gupta, CEO, Lupin said: "The approval is timely as Albuterol MDI is a key rescue inhalation product for asthma patients who are at an increased risk of COVID-19-related complications. We look forward to launching the product this quarter and expect a steady ramp-up through the fiscal year. Quoting IQVIA moving annual total June 2020 data, Lupin said the total Albuterol Sulfate Inhalation Aerosol market had US sales of approximately USD 2.9 billion, of which the ...

Lupin recalls around 561,000 pouches of birth control pills in US market

Drug major Lupin is recalling 5,60,922 pouches of a birth control product in the US, as per the US Food and Drug Administration (USFDA)

Nifty Pharma index rallies nearly 3%; Lupin surges 10%, Cipla, Cadila up 3%

All the 10 constituents of the Nifty Pharma index were trading in the green.

Lupin appoints K B S Anand, Punita Kumar Sinha as independent directors

Drug firm Lupin on Wednesday announced the appointment of K B S Anand and Punita Kumar-Sinha as independent directors. Anand most recently served as managing director and chief executive officer at Asian Paints. He currently serves as an independent director on the boards of Marico, Tata Chemicals and Borosil, Lupin said in a filing to BSE. Punita Kumar-Sinha brings significant governance and investment experience across India and North America. She founded Pacific Paradigm Advisors, an independent investment advisory and management firm, and was formerly a senior managing director at Blackstone, it added. She serves as an independent director for several companies, including Infosys, JSW Steel, Blackstone Embassy REIT and Rallis, Lupin said. "We are delighted to welcome Mr K B S Anand and Dr Punita Kumar-Sinha to our board. With their long and illustrious careers, they bring decades of experience in key areas such as innovation, strategy, capital markets and financial expertise

Lupin pharma launches generic asthma treatment drug in US market

Drug firm Lupin on Tuesday said it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market. The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added. The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing. According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid. The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added. Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.

Lupin, Sun Pharma recalling products in the US market, says USFDA

Leading drug makers Lupin and Sun Pharma are recalling different products in the US, according to the US Food and Drug Administration (USFDA).

Weak US sales drags Lupin's Q1 show, revival hinges on key launches

The company reported a sharp 21 per cent decline in revenues in the US, much higher than its peers

Lupin Q1 net profit drops 65% to Rs 107 crore slammed by Covid-19

Consolidated total revenue from operations stood at Rs 3,527.9 crore for the quarter under consideration. It was Rs 3,877.7 crore for the same period a year ago

Lupin plunges 6% as June quarter profit tanks 60% YoY to Rs 107 crore

EBITDA tood at Rs 531.4 cror for the quarter under review, down 34.7 per cent, from Rs 813.4 crore of Q1FY20, and by 27.6 per from Rs 733.9 crore logged in Q4FY20

Lupin alliance partner Concord gets USFDA nod for generic medicine

Concord has received approval from the US Food and Drug Administration (USFDA) to market the drug to prevent organ transplant rejection